Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Industrial Estimate
Composite Estimate
500 Stocks Estimate
Gold
Crude Oil
Central Oregon Stock Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Biogen Idec
(NQ:
BIIB
)
177.87
+0.09 (+0.05%)
Streaming Delayed Price
Updated: 4:00 PM EST, Dec 1, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
2,170
Open
177.87
Bid (Size)
176.50 (100)
Ask (Size)
178.27 (100)
Prev. Close
177.78
Today's Range
177.78 - 177.87
52wk Range
110.03 - 185.17
Shares Outstanding
145,800,000
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Stoke Therapeutics and Biogen Announce Presentations at the 2025 American Epilepsy Society Annual Meeting
December 01, 2025
From
Stoke Therapeutics, Inc.
Via
Business Wire
Novo Nordisk Shares Plunge as Alzheimer's Drug Trial Fails to Meet Primary Endpoint
November 24, 2025
Copenhagen, Denmark – November 24, 2025 – Novo Nordisk's (CPH: NOVO B) stock experienced a significant and immediate downturn today, plummeting by over 10% in early trading, following the announcement...
Via
MarketMinute
Performance
YTD
+18.6%
+18.6%
1 Month
+17.5%
+17.5%
3 Month
+27.4%
+27.4%
6 Month
+35.6%
+35.6%
1 Year
+8.3%
+8.3%
More News
Read More
Which S&P500 stocks are moving before the opening bell on Monday?
↗
November 24, 2025
Via
Chartmill
Earnings Scheduled For October 30, 2025
↗
October 30, 2025
Via
Benzinga
Biogen Licenses Vanqua Bio’s Immunology Drug In $1.06B Deal
↗
October 24, 2025
Via
Stocktwits
Biogen and Dayra Therapeutics Announce Research Collaboration to Discover and Develop Oral Macrocyclic Peptides for a Range of Immunological Conditions
November 24, 2025
From
Biogen Inc.
Via
GlobeNewswire
AbbVie, Biogen, BioMarin Pharmaceutical, DexCom, and Abbott Laboratories Stocks Trade Up, What You Need To Know
November 21, 2025
Via
StockStory
Topics
Economy
Government
World Trade
Biogen to Highlight New Lecanemab Data and Scientific Advances at the 18th Clinical Trials on Alzheimer’s Disease Conference
November 20, 2025
From
Biogen Inc.
Via
GlobeNewswire
Uncover the latest developments among S&P500 stocks in today's session.
↗
November 18, 2025
Via
Chartmill
Biogen and Stoke Therapeutics Announce Publication of Two-Year Natural History Data Demonstrating the Severity of Dravet Syndrome, Including Frequent Seizures and Significant Cognitive and Behavioral Impairments
November 17, 2025
From
Biogen Inc.
Via
GlobeNewswire
High Dose Regimen of Nusinersen Receives Positive CHMP Opinion for the Treatment of Spinal Muscular Atrophy
November 17, 2025
From
Biogen Inc.
Via
GlobeNewswire
Biogen Completes Acquisition of Alcyone Therapeutics
November 14, 2025
From
Biogen Inc.
Via
GlobeNewswire
Explore the top gainers and losers within the S&P500 index in today's session.
↗
November 13, 2025
Via
Chartmill
5 Insightful Analyst Questions From Biogen’s Q3 Earnings Call
November 06, 2025
Via
StockStory
Topics
Earnings
Biogen to Highlight Scientific Progress in Rare Kidney Disease at American Society of Nephrology (ASN) Kidney Week 2025
November 03, 2025
From
Biogen Inc.
Via
GlobeNewswire
BIIB Q3 Deep Dive: New Product Launches Offset Guidance Cut, R&D Pipeline Expands
October 31, 2025
Via
StockStory
Biogen (NASDAQ:BIIB) Beats Q3 Sales Expectations
October 30, 2025
Via
StockStory
Topics
Artificial Intelligence
Biogen Sinks Back Into A Buy Zone After Cutting Its Profit Guide
↗
October 30, 2025
Via
Investor's Business Daily
Examining the Future: Biogen's Earnings Outlook
↗
October 29, 2025
Via
Benzinga
Biogen (BIIB) Reports Earnings Tomorrow: What To Expect
October 28, 2025
Via
StockStory
Topics
Artificial Intelligence
Biogen's Immunology Pipeline Has Long-Term Potential: Analyst
↗
October 24, 2025
Via
Benzinga
Biogen Licenses Oral C5aR1 Antagonist from Vanqua Bio to Expand Immunology Portfolio
October 24, 2025
From
Biogen Inc.
Via
GlobeNewswire
3 Profitable Stocks We Steer Clear Of
October 24, 2025
Via
StockStory
Biogen to Present Additional Results from Phase 3 Study of Dapirolizumab Pegol in Systemic Lupus Erythematosus at ACR Convergence 2025
October 22, 2025
From
Biogen Inc.
Via
GlobeNewswire
ARPA-H Taps Former DARPA Innovator to Ignite High-Risk, High-Reward Health Tech Revolution
October 21, 2025
Via
TokenRing AI
Topics
Artificial Intelligence
Intellectual Property
Frequently Asked Questions
Is Biogen Idec publicly traded?
Yes, Biogen Idec is publicly traded.
What exchange does Biogen Idec trade on?
Biogen Idec trades on the Nasdaq Stock Market
What is the ticker symbol for Biogen Idec?
The ticker symbol for Biogen Idec is BIIB on the Nasdaq Stock Market
What is the current price of Biogen Idec?
The current price of Biogen Idec is 177.87
When was Biogen Idec last traded?
The last trade of Biogen Idec was at 12/01/25 04:00 PM ET
What is the market capitalization of Biogen Idec?
The market capitalization of Biogen Idec is 25.93B
How many shares of Biogen Idec are outstanding?
Biogen Idec has 26B shares outstanding.
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.